Colorectal cancer chemoprevention by 2 β-cyclodextrin inclusion compounds of auraptene and 4′-geranyloxyferulic acid

International Journal of Cancer

Volumn 126, Issue 4, 2010, Pages 830-840

  Tanaka, Takuji ^a,b   De Azevedo, Mariangela B M ^c   Durán, Nelson ^d   Alderete, Joel B ^e   Epifano, Francesco ^f   Genovese, Salvatore ^f   Tanaka, Mayu ^g   Tanaka, Takahiro ^h   Curini, Massimo ⁱ  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

^c INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e UNIVERSITY OF CONCEPCIÓN   (Chile)

^f UNIVERSITY OF CHIETI   (Italy)

^g KINJO GAKUIN UNIVERSITY   (Japan)

^h KANSAI UNIVERSITY OF HEALTH SCIENCES   (Japan)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

Author keywords

4 geranyloxyferulic acid; Antitumor activity; Auraptene; Inclusion compounds; cyclodextrin

Indexed keywords

3 (4' GERANYLOXY 3' METHOXYPHENYL) 2 TRANS PROPENOIC ACID; ANTINEOPLASTIC AGENT; AURAPTENE; AZOXYMETHANE; BETA CYCLODEXTRIN; DEXTRAN SULFATE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 74049153708     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24833     Document Type: Article

References (78)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. WHO Media Center. Cancer fact sheet No. 297. WHO, 2006.
3. Tanaka T. Colorectal carcinogenesis: review of human and experimental animal studies. J Carcinog 2009;8:5.
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
5. Rubin DT, Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol 2006;9: 211-20.
6. Tanaka T, Kohno H, Murakami M, Shimada R, Kagami S. Colitis-related rat colon carcinogenesis induced by 1-hydroxy-anthraquinone and methylazoxymethanol acetate (review). Oncol Rep 2000;7:501-8.
7. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94:965-73.
8. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006;27:162-9.
9. Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004;95:721-7.
10. Suzuki R, Miyamoto S, Yasui Y, Sugie S, Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 2007;7:84.
11. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitisrelated colon carcinogenesis in mice. Int J Cancer 2006;118:29336-42.
12. Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 2007;13:2519-25.
13. Kohno H, Suzuki R, Sugie S, Tanaka T. Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 2005;2005:69-76.
14. Tanaka T, Suzuki R, Kohno H, Sugie S, Takahashi M, Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for betacatenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005; 26:229-38.
15. Tanaka T, Kohno H, Suzuki R, Hata K, Sugie S, Niho N, Sakano K, Takahashi M, Wakabayashi K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 2006;118:25-34.
16. Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 2005;591: 110-22.
17. D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 2004;10:23-7.
18. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98.
19. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136: 1182-97.
20. Tanaka T, Yasui Y, Ishigamori-Suzuki R, Oyama T. Citrus compounds inhibit inflammation- and obesity-related colon carcinogenesis in mice. Nutr Cancer 2008; 60(Suppl 1):70-80.
21. Tanaka T, Yasui Y, Tanaka M, Oyama T, Rahman KM. Melatonin suppresses AOM/ DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009;177:128-36.
22. Kohno H, Suzuki R, Curini M, Epifano F, Maltese F, Gonzales SP, Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitisrelated colon carcinogenesis in mice. Int J Cancer 2006;118:2936-42.
23. Miyamoto S, Epifano F, Curini M, Genovese S, Kimi M, Ishigamori-Suzuki R, Yasui Y, Sugie S, Tanaka T. A novel prodrug of 40-geranyloxy-ferulic acid suppresses colitis-related colon carcinogenesis in mice. Nutr Cancer 2008; 60:675-84.
24. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1-11.
25. De Azevedo MBM, Alderete JB, Lino ACS, Loh W, Faljoni-Alario A, Duran N. Violacein/b-cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism. J Inclusion Phenom Macrocycl Chem 2000; 37:67-74.
26. De Azevedo MBM, Correa DHA, Carvalho CAA, Haun M, Duran N, Melo PS. Dehydrocrotonin and its b-cyclodextrin complex: cytotoxicity in V79 fibroblasts and rat cultured hepatocytes. Eur J Pharmacol 2005;510:17-24.
27. De Azevedo MBM, Melo PS, Justo GZ, Duran N, Haun M. Violacein and its b-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology 2003;186:217-25.
28. Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci 2008;97:2878-91.
29. Curini M, Epifano F, Genovese S, Marcotullio MC, Menghini L. 3-(40-Geranyloxy-30-Methoxyphenyl)-2-trans propenoic acid: a novel promising cancer chemopreventive agent. Anticancer Agents Med Chem 2006;6:571-7.
30. Epifano F, Genovese S, Curini M. Auraptene: phytochemical and pharmacological properties. In: Matsumoto T, editor. Phytochemistry research progressed. Hauppauge, NY: Nova Science Publishers, 2008.145-62.
31. Surh YJ. NF-kappa B and Nrf2 as potential chemopreventive targets of some antiinflammatory and antioxidative phytonutrients with anti-inflammatory and antioxidative activities. Asia Pac J Clin Nutr 2008;17(Suppl 1):269-72.
32. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008;13:2950-9.
33. Bharti AC, Aggarwal BB. Nuclear factorkappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64: 883-8.
34. Kwon KH, Barve A, Yu S, Huang MT, Kong AN. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol Sin 2007;28:1409-21.
35. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J. Cell Biochem 2007;102:580-92.
36. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
37. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008;13:5094-107.
38. Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/ STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008;9: 369-74.
39. Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, Sata M. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res 2007;27:3749-56.
40. Kwon KH, Murakami A, Hayashi R, Ohigashi H. Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 2005;337: 647-54.
41. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A, Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer 2009;124:264-71.
42. Watson AJ. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006;57:107-21.
43. Curini M, Epifano F, Genovese S. Synthesis of a novel prodrug of 3-(40-geranyloxy-30-methoxyphenyl)-2-trans-propenoic acid for colon delivery. Bioorg Med Chem Lett 2005;15:5049-52.
44. Curini M, Epifano F, Maltese F, Marcotullio MC, Tubaro A, Altinier G, Prieto Gonzales S, Rodriguez JC. Synthesis and anti-inflammatory activity of natural and semisynthetic geranyloxycoumarins. Bioorg Med Chem Lett 2004;14:2241-3.
45. De Azevedo MBM, Alderete J, Rodriguez JA, Souza AO, Rettori D, Torsoni MA, Faljoni-Alario A, Haun M, Duran N. Biological activities of violacein, a new antitumoral indole derivative, in an inclusion complex with beta-cyclodextrin. J Inclusion Phenom Macrocycl Chem 2000;37:93-101.
46. De Azevedo MBM, Zullo MAT, Alderete JB, De Azevedo MMM, Salva TJG, Duran N. Characterisation and properties of the inclusion complex of 24-epibrassinolide with beta-cyclodextrin. Plant Growth Reg 2002;37:233-40.
47. Carino SR, Tostmann H, Underhill RS, Logan J, Weerasekera G, Culp J, Davidson M, Duran RS. Real-time grazing incidence X-ray diffraction studies of polymerizing N-octadecyltrimethoxysilane Langmuir monolayers at the air/water interface. J Am Chem Soc 2001;123:767-8.
48. De Azevedo MBM, Duran N, Justo GZ, Melo PS, Brito ARMS, Almeida ABA, Haun M. Evaluation of the antiulcerogenic activity of violacein and its modulation by the inclusion complexation with betacyclodextrin. Can J Physiol Pharmacol 2003;81:387-96.
49. De Souza AO, Alderete JB, Faljoni-Alario A, Silva CL, Duran N. Physico-chemical characterization of the inclusion complex between a 2-propen-1-amine derivative and beta-cyclodextrin. J Chil Chem Soc 2005;50: 591-6.
50. Ward JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest 1974;30: 505-13.
51. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, Tanaka T. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007; 121: 2331-9.
52. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006;4:48.
53. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83.
54. Yoo SY, Lee SY, Yoo NC. Cytokine expression and cancer detection. Med Sci Monit 2009;15:RA49-56.
55. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
56. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005;5:46.
57. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006;66:11580-4.
58. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187-96.
59. Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006;12:7568-77.
60. Surh YJ, Na HK. NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2008;2:313-17.
61. Kim YS, Young MR, Bobe G, Colburn NH, Milner JA. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res 2009;2:200-8.
62. Janakiram NB, Rao CV. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 2008;29: 1-20.
63. Yasui Y, Kim M, Tanaka T. Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets. Curr Enzyme Inhibit 2009;5:1-26.
64. Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS, Lambeau G, Giardina C, Rosenberg DW. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003;24:307-15.
65. Inan MS, Place R, Tolmacheva V, Wang QS, Hubbard AK, Rosenberg DW, Giardina C. IkappaBbeta-related proteins in normal and transformed colonic epithelial cells. Mol Carcinog 2000;29:25-36.
66. Inan MS, Tolmacheva V, Wang QS, Rosenberg DW, Giardina C. Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the colon. Am J Physiol Gastrointest Liver Physiol 2000; 279:G1282-G1291.
67. Tong X, Yin L, Washington R, Rosenberg DW, Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem 2004; 265:171-83.
68. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008;9:375-80.
69. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005;1056: 218-33.
70. Kim M, Miyamoto S, Sugie S, Yasui Y, Ishigamori-Suzuki R, Murakami A, Nakagama H, Tanaka T. A tobacco-specific carcinogen, NNK, enhances AOM/DSSinduced colon carcinogenesis in male A/J mice. In Vivo 2008;22:557-63.
71. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma: correlation with clinicopathological factors. J Clin Pathol 2005;58:833-8.
72. Fenton JI, Hursting SD, Perkins SN, Hord NG. Interleukin-6 production by leptin treatment promotes cell proliferation in an Apc(Min/+) colon epithelial cell line. Carcinogenesis 2006;27:1507-15.
73. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005;2005:185-93.
74. Li JH, Zhou W, Liu K, Li HX, Wang L. Melatonin reduces the expression of chemokines in rat with trinitrobenzene sulfonic acid-induced colitis. Saudi Med J 2008;29:1088-94.
75. Epifano F, Genovese S, Sosa S, Tubaro A, Curini M. Synthesis and anti-inflammatory activity of 3-(4′-geranyloxy-3′-methoxyphenyl)-2- trans propenoic acid and its ester derivatives. Bioorg Med Chem Lett 2007;17:5709-14.
76. Tanaka T, Kawabata K, Kakumoto M, Hara A, Murakami A, Kuki W, Takahashi Y, Yonei H, Maeda M, Ota T, Odashima S, Yamane T, et al. Citrus auraptene exerts dose-dependent chemopreventive activity in rat large bowel tumorigenesis: the inhibition correlates with suppression of cell proliferation and lipid peroxidation and with induction of phase II drugmetabolizing enzymes. Cancer Res 1998;58: 2550-6.
77. Boukharta M, Jalbert G, Castonguay A. Biodistribution of ellagic acid and doserelated inhibition of lung tumorigenesis in A/J mice. Nutr Cancer 1992;18:181-9.
78. Kawabata K, Murakami A, Ohigashi H. Auraptene decreases the activity of matrix metalloproteinases in dextran sulfate sodium-induced ulcerative colitis in ICR mice. Biosci Biotechnol Biochem 2006;70: 3062-5.